141 related articles for article (PubMed ID: 7693039)
1. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
te Boekhorst PA; de Leeuw K; Schoester M; Wittebol S; Nooter K; Hagemeijer A; Löwenberg B; Sonneveld P
Blood; 1993 Nov; 82(10):3157-62. PubMed ID: 7693039
[TBL] [Abstract][Full Text] [Related]
2. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia.
Hart SM; Ganeshaguru K; Lyttelton MP; Prentice HG; Hoffbrand AV; Mehta AB
Leuk Lymphoma; 1993 Oct; 11(3-4):239-48. PubMed ID: 7903178
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
7. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
Lautier D; Bailly JD; Demur C; Herbert JM; Bousquet C; Laurent G
Int J Cancer; 1997 Apr; 71(2):292-9. PubMed ID: 9139856
[TBL] [Abstract][Full Text] [Related]
8. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
9. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
11. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
13. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
Marcelletti JF; Sikic BI; Cripe LD; Paietta E
Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
[TBL] [Abstract][Full Text] [Related]
14. Detection of P glycoprotein activity on normal and leukemic CD34+ cells.
Drenou B; Fardel O; Amiot L; Fauchet R
Leuk Res; 1993 Dec; 17(12):1031-5. PubMed ID: 7504150
[TBL] [Abstract][Full Text] [Related]
15. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
16. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia.
Pallis M; Turzanski J; Harrison G; Wheatley K; Langabeer S; Burnett AK; Russell NH
Br J Haematol; 1999 Feb; 104(2):307-12. PubMed ID: 10050713
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
[TBL] [Abstract][Full Text] [Related]
18. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.
Campos L; Guyotat D; Archimbaud E; Calmard-Oriol P; Tsuruo T; Troncy J; Treille D; Fiere D
Blood; 1992 Jan; 79(2):473-6. PubMed ID: 1370388
[TBL] [Abstract][Full Text] [Related]
20. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
